Analyst: Genmab may upgrade financial guidance based on Darzalex sales figures

Johnson & Johnson's sales figures for Darzalex in the second quarter are so good that Genmab, which developed the drug, may increase its financial expectations for the year, says senior analyst Søren Løntoft Hansen.

Photo: Joost Melis / Genmab / PR

Sydbank senior analyst Søren Løntoft Hansen expects Genmab to upgrade its total predicted market sales for 2021 after Johnson & Johnson's Q2 sales figures for Darzalex were revealed on Wednesday.

In the second quarter of this year, Johnson & Johnson sold USD 1.43bn worth of Darzalex, which is developed by Genmab. During the corresponding period last year, the US pharmaceutical company's Darzalex sales totaled USD 901m, meaning sales growth over the past year equates to 59.2 percent.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs